Cartesian Therapeutics In share price logo

Cartesian Therapeutics In Share Price

NASDAQ: RNAC

Small Cap

$6.60

+0.09

(+1.38%)

as on

Cartesian Therapeutics In Stock Performance

as on March 24, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $6.39
    $6.82
    downward going graph

    3.18%

    Downside

    3.33%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $5.98
    $16.62
    downward going graph

    9.39%

    Downside

    151.86%

    Upside

    downward going graph

Cartesian Therapeutics In share price movements today

Previous Close
$6.51
Open
$6.66
Volume
283.5K
Day's Low - High
$6.39 - $6.82
52 Week Low - High
$5.98 - $16.62

Cartesian Therapeutics In Historical Returns

1 Month Return
-6.73 %
3 Month Return
+ 1.24 %
1 Year Return
-59.44 %
3 Year Return
0 %
5 Year Return
0 %

Cartesian Therapeutics In Stock Fundamentals & Key Indicators

Check Cartesian Therapeutics In market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$169.3M

EPS (TTM)

-2.15

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.07%

PE Ratio (TTM)

-1.36

Industry PE ratio

0

PEG Ratio

0

EBITDA

-83.7M

Revenue (TTM)

2.8M

Profit Margin

0.00%

Return On Equity TTM

-7029.26%

Cartesian Therapeutics In Stock Valuation

Track how Cartesian Therapeutics In P/E has moved over time to understand its valuation trends.

Cartesian Therapeutics In in the last 5 years

  • Overview

  • Trends

Lowest (-82.30x)

June 30, 2024

Industry (0.00x)

March 23, 2026

Today (-1.36x)

March 23, 2026

Highest (-1.47x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -1.36x

Cartesian Therapeutics In vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cartesian Therapeutics In with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Cartesian Therapeutics In image
Cartesian Therapeutics In
BUY$169.3MNA-1.360.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.4B125.13%133.418.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.3B112.56%29.6732.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.6BNA1115.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$77.5B56.01%17.6731.41%

Stock Returns calculator for Cartesian Therapeutics In Stock including INR - Dollar returns

The Cartesian Therapeutics In stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

Cartesian Therapeutics In investment value today

Current value as on today

₹51,041

Returns

₹48,959

(-48.96%)

Returns from Cartesian Therapeutics In Stock

₹58,879 (-58.88%)

Dollar Returns*

₹9,919 (+9.92%)

Analyst Recommendation on Cartesian Therapeutics In Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Cartesian Therapeutics In. Average target price of $35.57

Cartesian Therapeutics In Share Price Target

Get share price movements and forecasts by analysts on Cartesian Therapeutics In.

What analysts predicted

81.45%UPSIDE

Target Price

$35.57

Current Price

$6.6

Analyzed by

11 Analysts

Target

$35.57

Cartesian Therapeutics In target price $35.57, a slight upside of 81.45% compared to current price of $6.6. According to 11 analysts rating.

Cartesian Therapeutics In Stock’s Investor Sentiment and Interest

Search interest for Cartesian Therapeutics In Stock has increased by 112% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:112% versus previous 30 day period

Cartesian Therapeutics In Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
6
8
5
33
0
0
1
0
0
0
Gross Profit
-6
8
5
33
0
0
1
0
-12
0
Operating Income
-13
-36
-13
13
-17
-26
-21
-21
-21
-21
EBITDA
-12
-196
-13
13
-23
-9
-20
16
-35
-21
Interest Expense
1
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
1
0
0
-
Income Before Tax
-9
-196
-56
13
-24
-9
-17
15
-35
-101
Income Tax Expense
1
-19
0
0
-
0
-
-
-
-9
Net Income
-9
-177
-56
13
-24
-10
-17
15
-35
-92
Net Profit Margin
-137.41%
-2149.26%
-973.01%
41.37%
-6248.84%
1350.86%
-1610.00%
5330.87%
-7942.92%
-9775.71%

Cartesian Therapeutics In Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
8
0
0
6
16
85
110
26
38
2
Gross Profit
8
0
0
6
16
85
108
26
38
2
Operating Income
-34
-63
-65
-52
-56
-4
14
-86
-43
-86
EBITDA
-34
-63
-62
-51
-65
-5
39
-235
-75
-86
Interest Expense
1
1
1
1
1
2
3
2
-
-
Depreciation
-
0
0
2
0
1
1
0
1
-
Income Before Tax
-36
-65
-65
-55
-68
-9
34
-238
-77
-139
Income Tax Expense
0
0
0
1
1
15
0
-19
0
-9
Net Income
-36
-65
-65
-55
-68
-25
35
-219
-77
-130
Net Profit Margin
-447.98%
-31556.04%
-7235.44%
-828.97%
-414.99%
-30.19%
31.94%
-844.91%
-198.97%
-4658.63%

Cartesian Therapeutics In Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-177
-56
13
-24
-10
-17
15
-35
-92
Operating Cash Flow
-23
-15
-14
13
-7
-23
-17
-15
-17
Investing Cash Flow
6
0
-1
-6
0
-1
-2
-1
0
Financing Cash Flow
14
43
0
124
0
-8
0
0
0
Change in Cash
-2
26
-15
131
-6
-32
-20
-16
-18

Cartesian Therapeutics In Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-65
-65
-55
-68
-25
35
-219
-77
-130
Operating Cash Flow
-52
-59
-51
34
-60
-31
-51
-23
-73
Investing Cash Flow
-2
25
0
0
-17
-15
34
-8
-5
Financing Cash Flow
66
0
105
14
52
39
-13
168
-8
Change in Cash
11
-33
52
48
-24
-7
-29
135
-87

Global Institutional Holdings in Cartesian Therapeutics In

Funds
Holdings
Erste Asset Management GmbH
1.02%
Privium Fund Management B.V.
0.65%
683 Capital Management LLC
0.88%
Renaissance Technologies Corp
0.15%
FMR Inc
5.16%
See all

Insights on Cartesian Therapeutics In

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, RNAC has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, RNAC stock has moved up by 349.0%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 298.0K → 947.0K (in $), with an average increase of 43.2% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 11.3% return, outperforming this stock by 70.7%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 15.88M → -92.57M (in $), with an average decrease of 241.9% per quarter

About Cartesian Therapeutics In

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
OrganisationCartesian Therapeutics In
Headquarters7495 New Horizon Way, Frederick, MD, United States, 21703
CEODr. Carsten Brunn Ph.D.
E-voting on sharesClick here to vote

Key Management of Cartesian Therapeutics In

Name

Title

Dr. Milos Miljkovic M.D., Ph.D.

Chief Medical Officer

Dr. Carsten Brunn Ph.D.

President, CEO & Chairman of the Board

Mr. Blaine T. Davis

Chief Financial Officer

Dr. Metin Kurtoglu M.D., Ph.D.

Consultant

Dr. Emily English Ph.D.

Chief Operating Officer

Ms. June Seymour

Chief Accounting Officer

Mr. Matthew Bartholomae J.D.

General Counsel & Secretary

FAQs

What is Cartesian Therapeutics In share price today?

Cartesian Therapeutics In share price today is $6.6 as on at the close of the market. Cartesian Therapeutics In share today touched a day high of $6.82 and a low of $6.39.

What is the 52 week high and 52 week low for Cartesian Therapeutics In share?

Cartesian Therapeutics In share touched a 52 week high of $16.62 on and a 52 week low of $5.98 on . Cartesian Therapeutics In stock price today i.e. is closed at $6.6,which is 60.30% down from its 52 week high and 10.37% up from its 52 week low.

What is Cartesian Therapeutics In's market capitalisation today?

Cartesian Therapeutics In market capitalisation is $0.00T as on .

How to invest in Cartesian Therapeutics In Stock (RNAC) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Cartesian Therapeutics In on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cartesian Therapeutics In Shares that will get you 0.2273 shares as per Cartesian Therapeutics In share price of $6.6 per share as on March 24, 2026 at 1:29 am IST.

What is the minimum amount required to buy Cartesian Therapeutics In Stock (RNAC) from India?

Indian investors can start investing in Cartesian Therapeutics In (RNAC) shares with as little as ₹94.058 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹940.58 in Cartesian Therapeutics In stock (as per the Rupee-Dollar exchange rate as on ). Based on Cartesian Therapeutics In share’s latest price of $6.6 as on March 24, 2026 at 1:29 am IST, you will get 1.5152 shares of Cartesian Therapeutics In. Learn more about fractional shares .